Evidence map›Paper›PMID 24152948›Full record

ArticlePancreas2013

Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop.

Dana K Andersen, Åke Andren-Sandberg, Eric J Duell, Michael Goggins, Murray Korc, Gloria M Petersen, Jill P Smith, David C Whitcomb

Open access · greenAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Pancreas, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 3 countries.

Dana K AndersenFrom the *Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; †Department of Surgery, Karolinska Institute, Stockholm, Sweden; ‡Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology, Barcelona, Spain; §Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; ∥Departments of Medicine and Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN; ¶Department of Epidemiology, Mayo Graduate School of Medicine, Rochester, MN; and #Departments of Medicine, Cell Biology and Physiology, and Human Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Åke Andren-Sandberg
Eric J Duell
Michael Goggins
Murray Korc
Gloria M Petersen
Jill P Smith
David C Whitcomb
Indiana University Bloomington · USInstitut Català d'Oncologia · ESJohns Hopkins University · USKarolinska Institutet · SEMayo Clinic · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USUniversity of Pittsburgh · US

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
Novel aspects of Epithelial-Mesenchymal Transition(EMT)in pancreatic cancerR01CA075059 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KORC, MURRAY · 1997 to 2018
$4.3M
Intramural NIH HHS Z99 DA999999Intramural NIH HHS Z99 DK999999Intramural NIH HHS Z99 OD999999NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA075059
6 · The paper itself

Abstract

A workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI) on "Pancreatitis-Diabetes-Pancreatic Cancer" focused on the risk factors of chronic pancreatitis (CP) and diabetes mellitus (DM) on the development of pancreatic ductal adenocarcinoma (PDAC). Sessions were held on (a) an overview of the problem of PDAC; (b) CP as a risk factor of PDAC; (c) DM as a risk factor of PDAC; (d) pancreatogenic, or type 3c, DM; (e) genomic associations of CP, DM, and PDAC; (f) surveillance of high-risk populations and early detection of PDAC; and (g) effects of DM treatment on PDAC. Recent data and current understandings of the mechanisms of CP- and DM-associated factors on PDAC development were discussed, and a detailed review of the possible risks of DM treatment on the development of PDAC was provided by representatives from academia, industry, and the Food and Drug Administration. The current status of possible biomarkers of PDAC and surveillance strategies for high-risk populations were discussed, and the gaps in knowledge and opportunities for further research were elucidated. A broad spectrum of expertise of the speakers and the discussants provided an unusually productive workshop, the highlights of which are summarized in the accompanying article.

Indexed as

Carcinoma, Pancreatic DuctalDiabetes ComplicationsDiabetes MellitusHumansNational Institute of Diabetes and Digestive and Kidney Diseases (U.S.)Pancreatic NeoplasmsPancreatitis, ChronicRisk FactorsUnited States

Identifiers

PMID24152948
PMCPMC3878448
OpenAlexW2053646449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.